Evidence map›Paper›PMID 40932535›Full record

ArticleMolecular biology reports2025

GSK-3 inhibitor induces apoptosis and cell cycle arrest in CD133

Eda Acikgoz, Berrin Ozdil, Gulperi Oktem, Huseyin Aktug, Murat Cetin Ragbetli, Cafer Tas

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Metabolic reprogramming and plasticity of cancer stem cells.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eda AcikgozDepartment of Histology and Embryology, Faculty of Medicine, Van Yüzüncü Yil University, Van, Turkey. edaacikgoz@yyu.edu.tr.
Berrin OzdilDepartment of Histology and Embryology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
Gulperi OktemDepartment of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey.
Huseyin AktugDepartment of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey.
Murat Cetin RagbetliDepartment of Histology and Embryology, Faculty of Medicine, Karamanoglu Mehmetbey University, Karaman, Turkey.
Cafer TasDepartment of Histology and Embryology, Faculty of Medicine, Van Yüzüncü Yil University, Van, Turkey.

Funding

Yüzüncü Yil Üniversitesi TYD-2021-9342
6 · The paper itself

Abstract

backgroundTreatment of advanced prostate cancer (PCa) is a major challenge due to the persistence of drug-resistant cancer stem cells (CSCs), which are mainly responsible for metastasis and recurrence. Therefore, the key to achieve an effective treatment approach in PCa is through the development of strategies targeting CSCs. GSK-3, also known as a moonlight kinase, is associated with multiple signaling pathways involved in embryonic development and cancer, including Wnt/β-catenin, Sonic hedgehog, and Notch. Strong evidence suggests that pharmacological inhibition of GSK-3 can eliminate the prostate cancer stem/progenitor-like population. The present study aims to evaluate the effects of GSK-3 inhibitor IX on CD133 METHODS AND

resultsFollowing treatment with various concentrations of GSK-3 inhibitor IX, we assessed cell viability, apoptosis, cell cycle, and multicellular tumor spheroids formation capacity. Furthermore, expression levels of components in the Notch signaling pathway due to GSK-3 inhibition were examined by immunofluorescence staining. The results revealed that GSK-3 inhibitor IX exhibited strong anti-proliferative effects by inducing apoptotic cell death, causing G0/G1 phase arrest of CD133

conclusionTogether, our data demonstrated that GSK-3 inhibitor IX effectively eliminated CD133

Indexed as

Glycogen Synthase Kinase 3Prostatic NeoplasmsAC133 AntigenApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalHumansHyaluronan ReceptorsMaleNeoplastic Stem CellsReceptors, NotchSignal TransductionAC133 AntigenCD44 protein, humanGlycogen Synthase Kinase 3Hyaluronan ReceptorsPROM1 protein, humanReceptors, NotchApoptosisCancer stem cellCell cycleGSK-3NotchProstate cancer

Identifiers

PMID40932535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.